| Identification | Back Directory | [Name]
Lavoltidine | [CAS]
76956-02-0 | [Synonyms]
Loxtidina
loxtidine
AH-234844
Lavoltidine
Lavoltidina
Lavoltidinum
Lavoltidine [inn:ban]
Lavoltidinum [inn-latin]
Lavoltidina [inn-spanish]
86160-82-9 (Hemisuccinate[1:1])
1-Methyl-5-[[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1H-1,2,4-triazole-3-methanol
1H-1,2,4-Triazole-3-methanol, 1-methyl-5-((3-(3-(1-piperidinylmethyl)phenoxy)propyl)amino)- | [Molecular Formula]
C19H29N5O2 | [MDL Number]
MFCD00866755 | [MOL File]
76956-02-0.mol | [Molecular Weight]
359.47 |
| Hazard Information | Back Directory | [Uses]
Anti-ulcerative (histamine H2-receptor block er). | [Definition]
ChEBI: Loxtidine is a triazole that consists of 1,2,4-triazole bearing a methyl substituent at position 1, a hydroxymethyl substituent at position 3 and a {3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino group at position 5. A highly potent and selective H2-receptor antagonist. It has a role as a H2-receptor antagonist. It is a member of triazoles, a member of piperidines, an aromatic ether and a primary alcohol. | [in vivo]
Lavoltidine (Loxtidine; 0.5 g/L; orally (drinking water); changed weekly; for 3 months) shows partial suppression of both gastric acid secretion and progression to neoplasia. Lavoltidine inhibits gastric atrophy, hyperplasia, and dysplasia in H felis-infected INS-GAS mice[1].
Lavoltidine treatment for 6 months inhibits gastric tumors in H felis-infected INS-GAS mice[1].
| Animal Model: | Male hypergastrinemic mice (INS-GAS mice) infected with Helicobacter felis[1] | | Dosage: | 0.5 g/L | | Administration: | Orally (drinking water); changed weekly; for 3 months | | Result: | Showed partial suppression of both gastric acid secretion and progression to neoplasia.
|
| [IC 50]
H2 Receptor |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|